Abstract | BACKGROUND: There have been no mortality/morbidity endpoint studies with losartan in Chinese heart failure patients. The objective was to evaluate the effects of high-dose vs. low-dose losartan on clinical outcomes in Chinese subjects with heart failure. METHODS: RESULTS: Median follow-up was 4.8 years. Baseline characteristics were generally similar to the overall HEAAL cohort. Overall, 120 (44.1%) subjects in the losartan 150 mg group and 137 (50.2%) subjects in the losartan 50 mg group died (any cause) or were hospitalized for heart failure (hazard ratio (OR) 0.807, 95%CI 0.631 - 1.031). There were no notable differences between treatment groups in the proportion of subjects with adverse experiences. CONCLUSION: The results of this post hoc analysis in Chinese subjects, although not powered to show significance, were generally consistent with the main study results, which demonstrated a significantly reduced risk of all cause death or hospitalization for heart failure with daily losartan 150 mg vs. losartan 50 mg in subjects with symptomatic heart failure and intolerance to ACE inhibitors, supporting the use of the higher dose for optimum clinical benefit.
|
Authors | Da-Yi Hu, Jun Huang, Nai-Sheng Cai, Wen-Ling Zhu, Yi-Shi Li, Rachid Massaad, Mary E Hanson, Kenneth Dickstein |
Journal | Chinese medical journal
(Chin Med J (Engl))
Vol. 125
Issue 21
Pg. 3868-74
(Nov 2012)
ISSN: 2542-5641 [Electronic] China |
PMID | 23106890
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin-Converting Enzyme Inhibitors
- Losartan
|
Topics |
- Angiotensin II Type 1 Receptor Blockers
(therapeutic use)
- Angiotensin-Converting Enzyme Inhibitors
(therapeutic use)
- Double-Blind Method
- Female
- Heart Failure
(drug therapy)
- Humans
- Losartan
(adverse effects, therapeutic use)
- Male
- Middle Aged
|